Johnson & Johnson Challenges the Constitutionality of FCA $1.6 Billion Verdict
Arent Fox Schiff – Following a record $1.6 billion jury verdict for off-label promotion of HIV drugs Prezista and Intelence, Johnson & Johnson (J&J) subsidiary Janssen Products LP appealed to the Third Circuit, mounting an expansive attack on the constitutionality of the False Claims Act (FCA) qui tam provisions.
🔒 Members Only · Compliance & Enforcement BriefYou’ve reached the member portion of this brief.Members read the full analysis and the source documents in every case digest, six days a week.
$750/year